JP2002539272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002539272A5 JP2002539272A5 JP2000606261A JP2000606261A JP2002539272A5 JP 2002539272 A5 JP2002539272 A5 JP 2002539272A5 JP 2000606261 A JP2000606261 A JP 2000606261A JP 2000606261 A JP2000606261 A JP 2000606261A JP 2002539272 A5 JP2002539272 A5 JP 2002539272A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- fractions
- nacl
- column
- crude
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/272,359 US6936258B1 (en) | 1999-03-19 | 1999-03-19 | Staphylococcus antigen and vaccine |
| US09/272,359 | 1999-03-19 | ||
| PCT/US2000/006922 WO2000056357A2 (en) | 1999-03-19 | 2000-03-17 | Staphylococcus antigen and vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002539272A JP2002539272A (ja) | 2002-11-19 |
| JP2002539272A5 true JP2002539272A5 (https=) | 2010-11-25 |
| JP4656728B2 JP4656728B2 (ja) | 2011-03-23 |
Family
ID=23039462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000606261A Expired - Fee Related JP4656728B2 (ja) | 1999-03-19 | 2000-03-17 | ブドウ球菌抗原及びワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6936258B1 (https=) |
| EP (1) | EP1162997B1 (https=) |
| JP (1) | JP4656728B2 (https=) |
| AT (1) | ATE320265T1 (https=) |
| AU (1) | AU773226B2 (https=) |
| BR (1) | BR0009157B1 (https=) |
| CA (1) | CA2366433C (https=) |
| CY (1) | CY1105500T1 (https=) |
| DE (1) | DE60026691T2 (https=) |
| DK (1) | DK1162997T3 (https=) |
| ES (1) | ES2261192T3 (https=) |
| MX (1) | MXPA01009476A (https=) |
| NZ (1) | NZ514455A (https=) |
| PT (1) | PT1162997E (https=) |
| WO (1) | WO2000056357A2 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294177B1 (en) | 1996-09-11 | 2001-09-25 | Nabi | Staphylococcus aureus antigen-containing whole cell vaccine |
| US6936258B1 (en) * | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| AU2002364740A1 (en) * | 2001-12-21 | 2003-07-30 | Biosynexus Incorporated | Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria |
| US20060134141A1 (en) * | 2004-12-14 | 2006-06-22 | Nabi Biopharmaceuticals | Glycoconjugate vaccines containing peptidoglycan |
| EP1850867A1 (en) * | 2005-01-10 | 2007-11-07 | Nabi Biopharmaceuticals | Method of treating staphylococcus aureus infection |
| TWI374892B (en) | 2005-06-13 | 2012-10-21 | Glaxosmithkline Biolog Sa | Use of panton-valentine leukocidin for treating and preventing staphylococcus infections |
| WO2007008904A2 (en) * | 2005-07-08 | 2007-01-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections |
| US20090317421A1 (en) | 2006-01-18 | 2009-12-24 | Dominique Missiakas | Compositions and methods related to staphylococcal bacterium proteins |
| MY148405A (en) | 2006-03-30 | 2013-04-30 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EP2043690A1 (en) | 2006-06-12 | 2009-04-08 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
| EP2185190B1 (en) | 2007-08-31 | 2015-06-24 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| EP2341929B1 (en) | 2008-10-06 | 2017-01-25 | University Of Chicago | Compositions and methods related to bacterial emp proteins |
| US8101190B2 (en) * | 2009-03-03 | 2012-01-24 | Ingen Biosciences | Method for diagnosing staphylococcal infections |
| ES2784957T3 (es) | 2009-04-03 | 2020-10-02 | Univ Chicago | Composiciones y métodos relacionados con variantes de la proteína A (SPA) |
| BRPI1011753B8 (pt) | 2009-06-22 | 2021-05-25 | Wyeth Llc | conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem |
| HUE036372T2 (hu) | 2009-06-22 | 2018-07-30 | Wyeth Llc | Staphylococcus aureus antigének immunogén készítményei |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| US8974799B2 (en) | 2009-09-30 | 2015-03-10 | Novartis Ag | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides |
| BR112012010223A2 (pt) | 2009-10-30 | 2016-12-06 | Novartis Ag | purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares |
| JP2013523818A (ja) | 2010-04-05 | 2013-06-17 | ザ・ユニバーシティー・オブ・シカゴ | 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法 |
| JP6002128B2 (ja) | 2010-07-02 | 2016-10-05 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | プロテインＡ（ＳｐＡ）変種に関連する組成物および方法 |
| US9095540B2 (en) | 2010-09-09 | 2015-08-04 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens |
| WO2012051498A2 (en) | 2010-10-15 | 2012-04-19 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
| DK2654784T3 (en) | 2010-12-22 | 2017-02-13 | Wyeth Llc | STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| WO2013009564A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Tyrosine ligation process |
| BR112014003315A2 (pt) | 2011-08-15 | 2017-03-01 | Univ Chicago | composições e métodos relacionados a anticorpos para a proteína a estafilocócica |
| EP2776069A1 (en) | 2011-11-07 | 2014-09-17 | Novartis AG | Carrier molecule comprising a spr0096 and a spr2021 antigen |
| US9115066B2 (en) | 2011-12-14 | 2015-08-25 | Indicator Systems International, Inc. | Trisubstituted methyl alcohols and their polymerizable derivatives |
| AU2013252883B2 (en) | 2012-04-26 | 2018-05-17 | University Of Chicago | Staphylococcal coagulase antigens and methods of their use |
| EP2841101B1 (en) | 2012-04-26 | 2019-08-07 | University Of Chicago | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease |
| SI2885007T1 (sl) | 2012-08-16 | 2018-12-31 | Pfizer Inc. | Postopki in kompozicije glikokonjugacij |
| EP3363806B1 (en) | 2012-12-20 | 2022-11-16 | Pfizer Inc. | Glycoconjugation process |
| US10125373B2 (en) | 2013-01-22 | 2018-11-13 | Arizona Board Of Regents On Behalf Of Arizona State University | Geminiviral vector for expression of rituximab |
| GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
| EP3019515B1 (en) | 2013-07-11 | 2019-08-21 | Novartis AG | Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase |
| IL312327B2 (en) | 2014-01-21 | 2026-02-01 | Pfizer | Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses |
| BR112016016580B1 (pt) | 2014-01-21 | 2024-01-09 | Pfizer Inc | Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina |
| CN120718167A (zh) | 2014-01-21 | 2025-09-30 | 辉瑞大药厂 | 肺炎链球菌荚膜多糖及其缀合物 |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP3104886B1 (en) | 2014-02-14 | 2018-10-17 | Pfizer Inc | Immunogenic glycoprotein conjugates |
| AU2015359503B2 (en) | 2014-12-10 | 2019-05-09 | Glaxosmithkline Biologicals Sa | Method of treatment |
| CN107427568B (zh) | 2015-01-15 | 2021-12-14 | 辉瑞公司 | 用于肺炎球菌疫苗中的免疫原性组合物 |
| PE20220774A1 (es) | 2015-05-04 | 2022-05-16 | Pfizer | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos |
| CN108367063A (zh) | 2015-07-21 | 2018-08-03 | 辉瑞公司 | 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途 |
| JP6884145B2 (ja) | 2015-11-20 | 2021-06-09 | ファイザー・インク | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 |
| US11246924B2 (en) | 2016-04-01 | 2022-02-15 | Duke University | Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| US11413344B2 (en) | 2017-01-20 | 2022-08-16 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| WO2019183500A1 (en) | 2018-03-23 | 2019-09-26 | Hung Chiung Yu | Coccidioides antigens and methods of their use |
| CA3120922A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| MX2021013833A (es) | 2019-05-14 | 2022-03-17 | Univ Chicago | Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa). |
| KR20230056727A (ko) | 2020-08-26 | 2023-04-27 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| KR20230097160A (ko) | 2020-11-04 | 2023-06-30 | 화이자 인코포레이티드 | 폐렴구균 백신에 사용하기 위한 면역원성 조성물 |
| CA3218544A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| WO2026038177A1 (en) | 2024-08-16 | 2026-02-19 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2619122B1 (fr) | 1987-08-03 | 1990-03-09 | Pasteur Institut | Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede |
| US7279162B1 (en) * | 1990-10-22 | 2007-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection |
| FR2682388B1 (fr) * | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal. |
| DE69233012T2 (de) * | 1991-11-22 | 2003-11-06 | Fattom, Ali Ibrahim | Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i |
| US5770208A (en) * | 1996-09-11 | 1998-06-23 | Nabi | Staphylococcus aureus B-linked hexosamine antigen |
| US6294177B1 (en) * | 1996-09-11 | 2001-09-25 | Nabi | Staphylococcus aureus antigen-containing whole cell vaccine |
| WO1998028002A1 (en) | 1996-12-20 | 1998-07-02 | Research Foundation Of The City University Of New York | A novel pathogenic coccoid organism, staphylococcus leei, with trophism for gastric mucin |
| US5965374A (en) * | 1997-10-16 | 1999-10-12 | Biowhittaker Technologies, Inc. | Glucan-specific assay |
| AU6033299A (en) * | 1998-09-14 | 2000-04-03 | Nabi | Compositions of beta-glucans and specific igiv |
| US7030101B2 (en) * | 1998-09-14 | 2006-04-18 | Nabi Biopharmaceuticals | Compositions of β-glucans and specific antibodies |
| US6936258B1 (en) * | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| US20030113350A1 (en) * | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
-
1999
- 1999-03-19 US US09/272,359 patent/US6936258B1/en not_active Expired - Fee Related
-
2000
- 2000-03-17 AT AT00916405T patent/ATE320265T1/de active
- 2000-03-17 PT PT00916405T patent/PT1162997E/pt unknown
- 2000-03-17 MX MXPA01009476A patent/MXPA01009476A/es active IP Right Grant
- 2000-03-17 DE DE60026691T patent/DE60026691T2/de not_active Expired - Lifetime
- 2000-03-17 BR BRPI0009157-0B1A patent/BR0009157B1/pt not_active IP Right Cessation
- 2000-03-17 DK DK00916405T patent/DK1162997T3/da active
- 2000-03-17 JP JP2000606261A patent/JP4656728B2/ja not_active Expired - Fee Related
- 2000-03-17 WO PCT/US2000/006922 patent/WO2000056357A2/en not_active Ceased
- 2000-03-17 ES ES00916405T patent/ES2261192T3/es not_active Expired - Lifetime
- 2000-03-17 NZ NZ514455A patent/NZ514455A/en not_active IP Right Cessation
- 2000-03-17 AU AU37513/00A patent/AU773226B2/en not_active Ceased
- 2000-03-17 EP EP00916405A patent/EP1162997B1/en not_active Expired - Lifetime
- 2000-03-17 CA CA2366433A patent/CA2366433C/en not_active Expired - Fee Related
-
2004
- 2004-12-20 US US11/014,997 patent/US7531633B2/en not_active Expired - Fee Related
-
2006
- 2006-05-12 CY CY20061100620T patent/CY1105500T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002539272A5 (https=) | ||
| Russell | Wall-associated protein antigens of Streptococcus mutans | |
| Kuramitsu | Characterization of extracellular glucosyltransferase activity of Steptococcus mutans | |
| Baker et al. | Immunochemical characterization of the" native" type III polysaccharide of group B Streptococcus. | |
| Wessels et al. | Structural determination and immunochemical characterization of the type V group B Streptococcus capsular polysaccharide. | |
| Svenson et al. | Immunochemistry of Salmonella O-antigens: preparation of an octasaccharide-bovine serum albumin immunogen representative of Salmonella serogroup B O-antigen and characterization of the antibody response | |
| Fournier et al. | Isolation of type 5 capsular polysaccharide from Staphylococcus aureus | |
| Sela et al. | Uridine-specific antibodies obtained with synthetic antigens | |
| Cassone et al. | Production and characterisation of a monoclonal antibody to a cell-surface, glucomannoprotein constituent of Candida albicans and other pathogenic Candida species | |
| Mukasa et al. | Extraction, purification, and chemical and immunological properties of the Streptococcus mutans group “a” polysaccharide cell wall antigen | |
| Fox et al. | The multiple molecular structure of the M proteins of group A streptococci. | |
| ATE236194T1 (de) | Antigene polysaccharidfragmente mit einer terminalen 2,5-anhydro-d-mannosegruppevon gruppe b-streptococcus, typ ii und typ iii, und daraus hergestellte konjugatimpfstoffe | |
| Mukasa et al. | Structure and immunological specificity of the Streptococcus mutans group b cell wall antigen | |
| Rennie et al. | Partial characterisation of Escherichia coli haemolysin | |
| JPH04501718A (ja) | きよう膜多糖類アドヘシン抗原、製造、精製および用途 | |
| Elovson | Biogenesis of plasma membrane glycoproteins. Purification and properties of two rat liver plasma membrane glycoproteins. | |
| Slade | Extraction of cell-wall polysaccharide antigen from streptococci | |
| Bundle et al. | Characterization of Brucella polysaccharide B | |
| Haahtela et al. | Type 1 fimbria-mediated adhesion of enteric bacteria to grass roots | |
| Houston et al. | Characterization of Salmonella toxin released by mitomycin C-treated cells | |
| Lindahl et al. | Binding of K99 fimbriae of enterotoxigenic Escherichia coli to pig small intestinal mucin glycopeptides | |
| Bleiweis et al. | Cell walls of Group D streptococci II. Chemical studies on the type 1 antigen purified from the autolytic digest of cell walls | |
| Guy et al. | The Capsular Polysaccharide of Type I Pneumococcus: I. PURIFICATION AND CHEMICAL MODIFICATION | |
| Knox et al. | Non-specific inhibition of the precipitin reaction between teichoic acids and antisera | |
| Suárez et al. | Production of capsular polysaccharide of Streptococcus pneumoniae type 14 and its purification by affinity chromatography |